Allergan Increases Sales
Posted by admin on May 1, 2010 in Allergan | 0 comments
Things are looking good for Allergan, Inc., the makers of BOTOX®.
For the quarter ending March 31, 2010, the pharmaceutical company reported total product net sales were $1,105.8 million, showing an increase of 11.2% over the first quarter in 2009. Perhaps sales were helped by the FDA approval of BOTOX®for another therapeutic purpose on March 9, 2010: to treat adults with upper limb spasticity suffering from increased muscle stiffness in the fingers, wrist and elbow. On the same day, amendments were also made to the agreement with Glaxo Group Limited regarding BOTOX® sales in Japan and China. Allergan maintains the rights to sell BOTOX® to be used for cosmetic purposes, while Glaxo maintains the rights to sell the product to be used for therapeutic purposes.
Allergan estimates that the total product net sales for the second quarter will range from $1,190 million to $1,230 million.